| Authors: |
Ibrahim EIK; Department of Pharmacy, Uppsala University, Uppsala, Sweden., Girdenyté M; Department of Pharmacy, Uppsala University, Uppsala, Sweden.; Pharmacy and Pharmacology Center, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania., Hu Y; Department of Pharmacy, Uppsala University, Uppsala, Sweden.; Non-Clinical Safety & DMPK, BioNTech SE, Mainz, Germany., Di Cesare Mannelli L; Department of Neuroscience, Psychology, Drug Research and Child Health - Neurofarba - Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Balayssac D; Direction de La Recherche Clinique Et de L'Innovation, Université Clermont Auvergne, INSERM, NEURO-DOL, CHU Clermont-Ferrand, Clermont-Ferrand, U1107, France., Busserolles J; Université Clermont Auvergne, INSERM, NEURO-DOL, Clermont-Ferrand, U1107, France., Theil D; Novartis Institutes for Biomedical Research, Cambridge, MA, USA.; Roche Pharmaceutical Research and Early Development , Roche Innovation Center, Basel, Switzerland., Roussignol G; Preclinical Safety, Sanofi, R&D, Montpellier, France., Perrault O; Preclinical Safety, Sanofi, R&D, Montpellier, France., Le Berre N; Preclinical Safety, Sanofi, R&D, Montpellier, France., Chanut F; Preclinical Safety, Sanofi, R&D, Chilly Mazarin & Vitry, France., Slaoui M; Preclinical Safety, Sanofi, R&D, Vitry, France., Loryan I; Department of Pharmacy, Uppsala University, Uppsala, Sweden. irena.loryan@uu.se., Friberg LE; Department of Pharmacy, Uppsala University, Uppsala, Sweden. lena.friberg@uu.se. |
